This OHSS incidence appears higher than in a previous GnRH antagonist trial of individualized follitropin delta using the same OHSS classification [7]; however, any reliable comparison should be based on a randomized trial comparing the incidence of OHSS in a long GnRH agonist with that in a GnRH antagonist protocol and such trial has been recently completed (NCT03809429). Here, GNRH1 is linked to ovarian hyperstimulation syndrome.